Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1 results about "Tumor suppressor gene" patented technology

A tumor suppressor gene, or antioncogene, is a gene that regulates a cell during cell division and replication. If the cells grow uncontrollably it could result in cancer. When a tumor suppressor gene is mutated it results in a loss or reduction in its function; in combination with other genetic mutations this could allow the cell to grow abnormally. The loss of function for these genes may be even more important than proto-oncogene/oncogene activation in the development of many different human cancer cells. Tumor suppressor genes can be grouped into categories including caretaker genes, gatekeeper genes, and landscaper genes; the classification schemes are evolving as medicine advances, learning from fields including molecular biology, genetics, and epigenetics.

Mutated gene set for tumor molecular typing and application thereof

ActiveCN117253542BMicrobiological testing/measurementProteomicsDNA methylationGenomics
The present application relates to the technical field of biological diagnosis, and particularly relates to a mutant gene set for tumor molecular typing and application thereof, wherein the mutant gene set comprises 82 mutant genes including DNA methylation modification related genes, histone modification related genes, chromatin remodeling related genes, TCR signal pathway related genes, PI3K-AKT signal pathway related genes, JAK-STAT signal pathway related genes, immune escape related genes, P53 signal pathway related genes, tumor suppressor genes and NOTCH signal pathway related genes. The mutant gene set can be used for molecular typing, targeted therapy and overall survival prediction of intranodal peripheral T-cell lymphoma. The mutant gene set is verified by clinical trials, and is suitable for all primary and relapsed PTCL patients, relapsed or refractory peripheral T-cell lymphoma umbrella study based on genomics typing and PTCL patients receiving different treatment schemes, and has a very wide application range.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1